Aurora Spine (ASG) Q3 2024 earnings summary

Executive summary

• Achieved first profitable quarter with net income of $71,120, driven by strong sales growth and cost control initiatives.

• Revenue reached $4.8 million, a 21% increase year-over-year and fourth consecutive quarter above $4 million.

• Strategic expansion of sales force, targeted underserved markets, and advanced training contributed to significant sales growth.

• Robust demand in pain management, especially for SiLO TFX and ZIP 51 implants, fueled results.

• Continued expansion in pain management sector and increased market reach through new sales leadership.

Financial highlights

• Q3 2024 revenue: $4.8 million, up 21% from Q3 2023 and 16.8% sequentially from Q2 2024.

• Net income: $71,120, a turnaround from a $249,618 net loss in Q3 2023.

• Gross margin improved to 60.5% from 59.7% year-over-year.

• Operating expenses: $2.81 million, mainly due to sales force expansion, representing 59% of sales.

• EBITDAC for Q3: $380,117, up from $120,796 in Q3 2023; fifth consecutive quarter of positive EBITDAC.

Outlook and guidance

• Management targets $5 million quarterly revenue in 2025, aiming for $20 million+ annual sales.

• Q4 2024 has started strong; focus remains on surpassing $4.8 million in quarterly revenue.

• Anticipates significant growth from new products (Osteo Onyx, DEXA line), expanded sales force, and new training labs.

• Continued momentum expected with multicenter studies and expansion into new regions.

• Focus on innovation, superior patient outcomes, and maximizing shareholder value.